Default company panoramic image

Halo Healthcare Inc.

A diagnostics company for early detection of breast cancer with FDA, CE cleared risk assessment test and diagnostics test in development.

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location Irvine, CA, USA
  • Currency USD
  • Founded May 2012
  • Employees 6
  • Website

Company Summary

Halo HC is a 2012 restructured and recapitalized growth company, founded as NeoMatrix LLC. The Company provides women with early, affordable, noninvasive, breast cancer detection tests performed in Gyn offices. Early detection saves lives and reduces healthcare costs. FDA cleared HALO® Breast Test provides risk of developing breast cancer. The Aura lab assay is licensed IP for a biomolecular diagnostic test. Strong CPT codes exist for both.


  • Default avatar
    France Dixon Helfer

    30 years in healthcare, R&D, corporate development, operations, international sales and marketing for Fortune 500 companies and start-up companies including executive positions at Medtronic, Sorin, Xenotech Labs (acquired by MDT), Eclipse Surgical, MDDataDirect; raised $12M. Founder of Pegasus Biologics, raised $32M, and in under 3 years, built the company into an emerging growth revenue company with robust product pipeline, Mentor UCLA, Chapman.

  • Default avatar
    Arlene Silvergleid Bumb

    Arlene is a seasoned executive with a strong track record of achievements over 30 years in marketing/marketing research, due diligence, PR, positioning and branding, product launches, and business development for many medical device companies. Executive marketing for Fortune 500 companies and start-ups including St Jude Medical, Beckman, Pegasus. She has been an advisor to well over 40 medical device companies.

  • Default avatar
    Tom Ritter

    Tom has worked with large companies JNJ and worked with market focused companies Mentor Corporation, development stage companies. The industry sectors with direct relevance to HaloHC include aesthetic and plastic surgery, tissue engineering, and wound management. Dr. Ritter has experience in commercializing products that require clinical trials (class III) as well as those that require a premarket notification (class II) prior to market.

  • Default avatar
    Stephen Schurr

    Steve has 15+ years direct sales and distribution experience in U.S. and global launches and support in the medical industry. Successfully helped launch several startup companies growing multiple million dollar territories in a short period of time as both a distribution partner and as corporate senior sales management. The creation of these new market territories helped two of those startups sell to larger companies for more than $250M each.


  • Default avatar
    Casey McGlynn, Scott Murano, James Huie, WSGR
    Default avatar
    Marie May, CPA (independent)

Previous Investors

  • Default avatar
    Waveland Capital Partners, Private Equity Firm
    Default avatar
    Angel Investors